The Asia Pacific Opioids Market is expected to witness market growth of 3.5% CAGR during the forecast period (2021 2027).
Synthetic opioids (e.g., morphine and codeine) impact the same regions of the brain as natural opioids (e.g., morphine and codeine) to provide analgesic (pain-relieving) effects. Natural opioids, on the other hand, are naturally occurring compounds derived from the seed pods of specific poppy types. Fentanyl and methadone, for example, are synthetic opioids that have been approved for medicinal usage. In the late 1970s and 1980s, illicitly manufactured synthetic opioids structurally linked to the Schedule II opioid painkiller fentanyl were trafficked and misused on the West Coast. DEA controlled alphamethylfentanyl, 3-methylthiofentanyl, acetyl-alphamethylfentanyl, beta-hydroxy-3-methylfentanyl, alpha-methylthiofentanyl, thiofentanyl, betahydroxyfentanyl, para-fluorofentanyl, and 3-methylfentanyl in the 1980s.
Chronic pain is long-term pain that lasts longer than the normal recovery period or comes in conjunction with a chronic health condition like arthritis. Chronic pain can be intermittent or persistent. It may cause people to be unable to work, eat well, engage in physical activity, or simply enjoy life.
China is the world's second-largest pharmaceutical market, and it's flourishing due to two major factors: large-scale capital investment and strong increases in productivity. These two variables suggest that the country will be a desirable investment destination as well as a source of huge local savings. The country has been transitioning from a low-income to a more market-oriented economy since the 1970s. Due to its large-scale manufacturing capacity and high opioid consumption, China is witnessing a surge in the regional market. In recent years, both large and small pharmaceutical companies have made significant investments in research and development. Since most medications in the pipeline are nearing completion and will be ready by the end of the decade, opioid demand is expected to rise. In underdeveloped countries, it is easier to find patients for clinical studies.
The China market dominated the Asia Pacific Opioids Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $421.2 million by 2027. The Japan market is poised to grow at a CAGR of 2.9% during (2021 - 2027). Additionally, The India market is expected to witness a CAGR of 4.3% during (2021 - 2027).
Based on Application, the market is segmented into Pain Management, Cough Treatment and Diarrhea Treatment. Based on Product Type, the market is segmented into Methadone, Oxycodone, Hydrocodone, Fentanyl, Codeine, Morphine and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Endo International PLC, Mallinckrodt PLC, Sanofi S.A., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., and Purdue Pharma L.P.
Synthetic opioids (e.g., morphine and codeine) impact the same regions of the brain as natural opioids (e.g., morphine and codeine) to provide analgesic (pain-relieving) effects. Natural opioids, on the other hand, are naturally occurring compounds derived from the seed pods of specific poppy types. Fentanyl and methadone, for example, are synthetic opioids that have been approved for medicinal usage. In the late 1970s and 1980s, illicitly manufactured synthetic opioids structurally linked to the Schedule II opioid painkiller fentanyl were trafficked and misused on the West Coast. DEA controlled alphamethylfentanyl, 3-methylthiofentanyl, acetyl-alphamethylfentanyl, beta-hydroxy-3-methylfentanyl, alpha-methylthiofentanyl, thiofentanyl, betahydroxyfentanyl, para-fluorofentanyl, and 3-methylfentanyl in the 1980s.
Chronic pain is long-term pain that lasts longer than the normal recovery period or comes in conjunction with a chronic health condition like arthritis. Chronic pain can be intermittent or persistent. It may cause people to be unable to work, eat well, engage in physical activity, or simply enjoy life.
China is the world's second-largest pharmaceutical market, and it's flourishing due to two major factors: large-scale capital investment and strong increases in productivity. These two variables suggest that the country will be a desirable investment destination as well as a source of huge local savings. The country has been transitioning from a low-income to a more market-oriented economy since the 1970s. Due to its large-scale manufacturing capacity and high opioid consumption, China is witnessing a surge in the regional market. In recent years, both large and small pharmaceutical companies have made significant investments in research and development. Since most medications in the pipeline are nearing completion and will be ready by the end of the decade, opioid demand is expected to rise. In underdeveloped countries, it is easier to find patients for clinical studies.
The China market dominated the Asia Pacific Opioids Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $421.2 million by 2027. The Japan market is poised to grow at a CAGR of 2.9% during (2021 - 2027). Additionally, The India market is expected to witness a CAGR of 4.3% during (2021 - 2027).
Based on Application, the market is segmented into Pain Management, Cough Treatment and Diarrhea Treatment. Based on Product Type, the market is segmented into Methadone, Oxycodone, Hydrocodone, Fentanyl, Codeine, Morphine and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Endo International PLC, Mallinckrodt PLC, Sanofi S.A., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., and Purdue Pharma L.P.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Pain Management
- Cough Treatment and
- Diarrhea Treatment
By Product Type
- Methadone
- Oxycodone
- Hydrocodone
- Fentanyl
- Codeine
- Morphine and
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Endo International PLC
- Mallinckrodt PLC
- Sanofi S.A.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Purdue Pharma L.P.
Unique Offerings from the publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Opioids Market by Application
Chapter 4. Asia Pacific Opioids Market by Product Type
Chapter 5. Asia Pacific Opioids Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Johnson & Johnson
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Endo International PLC
- Mallinckrodt PLC
- Sanofi S.A.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Purdue Pharma L.P.
Methodology
LOADING...
